



DEPARTMENT OF HEALTH AND HUMAN SERVICES

m791N

Food and Drug Administration  
Atlanta District Office

purged RJW  
HFI-35

60 8th Street, N.E.  
Atlanta, Georgia 30309

April 2, 1997

**CERTIFIED MAIL**  
**RETURN RECEIPT REQUESTED**

Fred Hinson, Administrator  
Anson County Hospital  
500 Morven Road  
Wadesboro, North Carolina 28170

**WARNING LETTER**

Inspection ID: 183251

Dear Mr. Hinson:

Your facility was inspected on February 27, 1997, by a representative of the North Carolina Department of Environment, Health, and Natural Resources (NCDEHNR), acting on behalf of the Food and Drug Administration (FDA). This inspection revealed that your facility failed to comply with certain Quality Standards for Mammography (MQSA) as specified in Title 21, Code of Federal Regulations (CFR), Part 900.12, as follows:

The interpreting physician, [REDACTED], is unqualified to interpret mammograms due to the lack of both board certification from any of the approved boards and two months full-time training in the interpretation of mammograms.

The specific deficiencies noted above appeared under the Level 1 heading on your MQSA Facility Inspection Report, which was issued at the close of the inspection. These deficiencies may be symptomatic of serious underlying problems that could compromise the quality of mammography at your facility.

In addition, your response should address the Level 2 noncompliances that were listed on the inspection report provided to you at the close of the inspection. These Level 2 noncompliances are:

The interpreting physician's, [REDACTED], initial experience was inadequate (reading and interpreting mammograms from the examinations of at least 240 patients in 6 months).

**It is your responsibility to ensure adherence to each requirement of the Mammography Quality Standards Act of 1992 (MQSA) and FDA's regulations. You are responsible for investigating and determining the causes of the deficiencies that the inspection identifies and promptly initiate permanent corrective actions.**

**If you fail to promptly correct these deficiencies, FDA may, without further notice, initiate regulatory action. Under MQSA, FDA may:**

- ▶ **impose civil money penalties on a facility of up to \$10,000 for each failure to substantially comply with, or each day of failure to substantially comply with, the standards;**
- ▶ **suspend or revoke a facility's FDA certificate for failure to comply with the standards;**
- ▶ **seek an injunction in federal court to prohibit any mammography activity that constitutes a serious risk to human health.**

**Please note that FDA regulations do not preclude a State from enforcing its own State mammography laws and regulations. In some cases, these requirements may be more stringent than FDA's. When you plan your corrective action(s), therefore, you should consider the more stringent State requirements, if any.**

**Within 15 working days after receiving this letter, you should notify FDA in writing of:**

- **the specific steps you have taken to correct all of the violations noted in this letter;**
- **each step your facility is taking to prevent the recurrence of similar violations;**
- **equipment settings (including technique factors), raw test data, and calculated final results, where appropriate; and**
- **sample records that demonstrate proper recordkeeping procedures, if the noncompliance were found relate to quality control or other records. (Note: Patient names or identification should be deleted from any copies submitted.)**

**If your facility is unable to complete the corrective action within 15 working days, you should state the reason for the delay and the time within which corrections will be completed.**

**Please send the original copy of your response to (NOTE: If phantom image is required for corrective action, please submit to (NCDEHNR):**

Food and Drug Administration  
Compliance Enforcement Branch  
60 8th Street, NE  
Atlanta, Georgia 30309

With a copy to:

North Carolina Department of Environment,  
Health, and Natural Resources  
3825 Barrett Drive  
Raleigh, NC 27609-7221

and

Debbie Hahn  
Food and Drug Administration  
5701 Executive Center Drive, Suite 104  
Charlotte, North Carolina 28212

You may choose to address both FDA and State requirements in your response. If you have any questions regarding this letter or how to ensure you are meeting MQSA standards, please call Debbie Hahn at 704\344-6116.

Sincerely yours,



Ballard H. Graham, Director  
Atlanta District

HFI-35  
JJM  
HFA-224  
HFC-210  
HFZ-300  
HFC-240  
HFZ-306  
HFZ-322  
HFA-244  
HFC-230  
HFZ-240  
HFZ-242  
NCDEHNR  
T. TROUT  
REK  
TURNER  
CLT-RP, DAH  
C. FOULKS  
FILE  
LG. JKT  
P. MILLS